Need for a national epilepsy control program

Tripathi, Manjari; Dc, Jain; Devi, M Gourie; Jain, Satish; Saxena, V. S.; Chandra, P. Sarat; Radhakrishnan, Kurupath; Behari, Madhuri; Gupta, Mukesh Kumar; Puri, Vinita; Mehndiratta, Manmohan; Bala, Kiran; Krishnan, Anand; Rawat, Sushma; Pu, Shah; Gulati, Sheffali; Johri, S; Nadkarni, VV; Chandra, Prakash; Bachani, Damodar

doi:10.4103/0972-2327.94989

Cited by 29 publications

(31 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to these studies, EIs reported having lost friends and having felt isolated and rejected by the community after a seizure (19,22) . It is also noteworthy that findings obtained in other studies (23) , similarly to the ones found in this research, show that individuals with limited knowledge about epilepsy may be frightened by the physical manifestation of seizures, characteristic of epilepsy, which may contribute to the perpetuation of stigma.…”

Section: Discussionsupporting

confidence: 86%

A pessoa com epilepsia: percepções acerca da doença e implicações na qualidade de vida

Hopker

Berberian

Massi

et al. 2017

CoDAS

View full text Add to dashboard Cite

RESUMO Objetivo Analisar percepções de pessoas com epilepsia acerca da doença e seu impacto na qualidade de vida. Método Trata-se de um estudo qualitativo e quantitativo de corte transversal realizado em hospital de referência terciária, vinculado ao Sistema Único de Saúde. Participaram do estudo 30 pessoas com o diagnóstico de epilepsia de lobo temporal refratária. Foi aplicado questionário para a coleta dos dados sociodemográficos e clínicos, bem como das percepções acerca da doença. Avaliou-se a qualidade de vida por meio do Subjective Handicap of Epilepsye e o estigma pela Escala Estigma na Epilepsia. Resultados Foi encontrada significância na relação entre estigma e qualidade de vida com os domínios trabalho e social/pessoal, entre estigma e percepções sobre a epilepsia. As respostas fornecidas pelos participantes foram organizadas em quatro categorias: definições e causas; crises e tratamento; impacto familiar e social; impacto na vida das pessoas. Conclusão Evidenciou-se o predomínio do conhecimento restrito dos participantes acerca da epilepsia e o impacto negativo que o estigma relacionado a tal doença acarreta na qualidade de vida. Pode-se verificar que a qualidade de vida e o estigma estão diretamente relacionados ao conhecimento dos participantes sobre a epilepsia. Ressalta-se a necessidade do implemento de programas e ações que objetivem: proporcionar maior conhecimento sobre a epilepsia por parte do paciente e de seus familiares; favorecer a comunicação entre os profissionais de saúde e as PCEs; promover a participação do paciente e de seus familiares na gestão do tratamento.

show abstract

Section: Discussionsupporting

confidence: 86%

A pessoa com epilepsia: percepções acerca da doença e implicações na qualidade de vida

Hopker

Berberian

Massi

et al. 2017

CoDAS

View full text Add to dashboard Cite

show abstract

“…The plant has different names in different languages of India such as: English: Ridged gourd, angled loofah, ribbed gourd, Chinese okra, silk squash (En); Hindi: Turai, Kadaviturai; Marathi: Dodaka; Sanskrit: Dhamargava, Koshataki; Bengali: Titotorai, Titojhinga, Titodhundal, Jhinga, Ghoshalata; Kannada: Kahire, Kahi heere, Naaga daali balli; Malayalam: Athanga; Tamil: Itukari, Itukarikkoti, Kacappi, Kacappuppirkku, Kaccam, Kaippuppirkku, Karniti; Telugu: Adavibira, Chedubira, Sendubirai, Adavi beera, Chathi beera (Nadkarni, 1996). …”

Section: Botanical Aspectsmentioning

confidence: 99%

“…The dried fruit powder is useful in preventing premature graying of hair. The root of the plant is laxative and used in dropsy (Nadkarni, 1996). …”

Section: Traditional Uses and Ethnopharmacologymentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Potential of Luffa acutangula: A Review on Its Traditional Uses, Phytochemistry, Pharmacology and Toxicological Aspects

Shendge

Belemkar

2018

Front. Pharmacol.

View full text Add to dashboard Cite

Luffa acutangula (Cucurbitaceae), a perennial plant grows mainly in India, Southeast Asia, China, Japan, Egypt, and other parts of Africa, it is widely used in the traditional Indian medicinal system to treat various health conditions. The plant has been used in jaundice, diabetes, hemorrhoids, dysentery, headache, ringworm infection, and leprosy. More than 50 chemical compounds have been isolated from a plant which mainly comprises flavonoids, anthraquinones, proteins, fatty acids, saponin triterpene, volatile components, and other phytoconstituents. Crude extract of plant and its isolated compounds possess broad pharmacological activities such as antidiabetic, hepatoprotective, antiulcer, anticancer, immunomodulatory, antihyperlipidemic, antioxidant, antimicrobial, CNS depressant, analgesic, and anti-inflammatory. The toxicological evaluation in preclinical studies reported safety of the plant for human consumption, but comprehensive evaluation in clinical studies is required. However, further investigation is necessary for transformation of experience based treatment of plant into evidence based information. Evaluation of pharmacological activity with indicative biomarkers will help to reveal the mechanism of action of chemical constituents of plant extract. The data from preclinical studies recommends clinical evaluation of safety and efficacy of the plant. The current paper summarizes up-to-date information about a review of the traditional uses, phytochemistry, pharmacological activities, and toxicology to highlight the future prospects of the plant.

show abstract

“…The second is to educate locally practising doctors and get them to take on a greater role in epilepsy care with support from specialists [7]. The exact operational details of these systems of care has not been fully documented but if either group is to take over a greater role in epilepsy care they will need some tools to help them.…”

Section: Introductionmentioning

confidence: 99%